DiaMedica Therapeutics just crossed two catalysts in 48 hours, and short sellers are watching carefully.
Q1 2026 results, released after market close on May 6, came in at -$0.19 per share — inline with expectations. That matched but did not beat, which matters for a clinical-stage name trading almost entirely on pipeline momentum. Simultaneously, the European Stroke Organisation Conference (ESOC) kicked off in Maastricht on May 6 and runs through May 8. DiaMedica's DM199 ischemic stroke data is on the table at that forum — making this week a genuine two-front test for investor confidence.
Short positioning reflects that uncertainty. With 9% of the free float sold short, this is a heavily shorted name for its size. Short interest has eased slightly on the week — down under 1% from the prior reading — but the one-month picture is more telling: shorts have added roughly 6% to their position over the past 30 days. The ORTEX short score is running at 84.2, a level that has held remarkably steady across the past two weeks. That consistency signals no meaningful capitulation from bears — they are not rushing for the exit ahead of either catalyst.
The lending market reinforces the cautious tone. Availability has tightened to around 17% of short interest — firmly in the "tight" zone — meaning for every share already borrowed, fewer than one new share is readily available to borrow. That has loosened a fraction from early April's peak, when the borrow market was even tighter, but the structural tension remains. Cost to borrow is modest at just over 1%, down around 4% on the week, suggesting borrowers are not yet paying a premium to hold the position despite the constrained pool.
Options traders are leaning the other way. The put/call ratio has dropped to just 0.12, well below its 20-day average of 0.18. That marks one of the most call-heavy readings of the past year — the 52-week high on the PCR is 1.10, and the current reading is near the low end of the range at 0.12. This is not a defensive setup. Options positioning tilts towards bulls expecting a positive surprise from the ESOC data or from Q1 commentary on DM199's preeclampsia cohort.
The Street endorses the bull case, though the most recent formal coverage is dated. All five tracked analysts rate DMAC a buy. Cantor Fitzgerald initiated at Overweight in November 2025 with a $25 target — a notable step up from the sub-$15 targets from HC Wainwright and Craig-Hallum. At $6.25, the stock trades at a steep discount to even the more conservative targets, though the wide gap between the Cantor price target and current trading levels is worth treating with caution given the stock's clinical-stage risk. The bear case centres on DM199's prior difficulty extending gestation in preeclampsia studies, financing risk, and safety concerns including angioedema — real hurdles that explain why shorts remain committed despite the bullish analyst consensus.
Institutional ownership adds a further layer of complexity. Jan Stahlberg, the top holder at just over 16% of shares, added more than 1 million shares in the last reported quarter. The entire insider register shows a heavy cluster of net buying across late 2025, with Stahlberg alone accumulating over $7.9 million of stock across multiple days in November. That accumulation now sits above current prices — the November purchases ranged from roughly $6.50 to $8.60 — which frames this week's $6.25 close as a continued test of insider conviction.
The ESOC presentation and the Q1 earnings call on May 7 are now the immediate focal points. With short interest firm, options tilted bullish, and a key insider holding at a cost basis above market, how management frames the DM199 stroke data and any preeclampsia cohort updates will shape how both sides of this trade respond.
See the live data behind this article on ORTEX.
Open DMAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
